Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Siglec-G represses DAMP-mediated effects on T cells
Tomomi Toubai, … , Yang Liu, Pavan Reddy
Tomomi Toubai, … , Yang Liu, Pavan Reddy
Published July 20, 2017
Citation Information: JCI Insight. 2017;2(14):e92293. https://doi.org/10.1172/jci.insight.92293.
View: Text | PDF
Research Article Immunology Transplantation

Siglec-G represses DAMP-mediated effects on T cells

  • Text
  • PDF
Abstract

The role of negative regulators or suppressors of the damage-associated molecular pattern–mediated (DAMP-mediated) stimulation of innate immune responses is being increasingly appreciated. However, the presence and function of suppressors of DAMP-mediated effects on T cells, and whether they can be targeted to mitigate T cell–dependent immunopathology remain unknown. Sialic acid–binding immunoglobulin-like lectin G (Siglec-G) is a negative regulator of DAMP-mediated responses in innate immune cells, but its T cell–autonomous role is unknown. Utilizing loss-of-function–based (genetic knockout) and gain-of-function–based (agonist) approaches, we demonstrate that in the presence of certain DAMPs, Siglec-G suppressed in vitro and in vivo T cell responses. We also demonstrate that its T cell–autonomous role is critical for modulating the severity of the T cell–mediated immunopathology, graft-versus-host disease (GVHD). Enhancing the Siglec-G signaling in donor T cells with its agonist, a CD24Fc fusion protein, ameliorated GVHD while preserving sufficient graft-versus-tumor (GVT) effects in vivo. Collectively, these data demonstrate that Siglec-G is a potentially novel negative regulator of T cell responses, which can be targeted to mitigate GVHD.

Authors

Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Cynthia Zajac, Chen Liu, Thomas Braun, Hideaki Fujiwara, Julia Wu, Yaping Sun, Stuart Brabbs, Hiroya Tamaki, John Magenau, Pang Zheng, Yang Liu, Pavan Reddy

×

Figure 2

Siglec-G regulates in vivo T cell responses in a cell-autonomous manner.

Options: View larger image (or click on image) Download as PowerPoint
Siglec-G regulates in vivo T cell responses in a cell-autonomous manner....
(A–F) BALB/c animals received 8.5 Gy on day –1 and were transplanted with 0.75 × 106 CD90.2+ splenic T cells from either syngeneic BALB/c or allogeneic MHC-mismatched B6 WT or B6 Siglec-G–/– animals along with 5 × 106 T cell–depleted bone marrow (TCD-BM) cells from either BALB/c or B6 donors. (A and B) Donor T cell (H-2Kb+CD4+CD8+) expansion in the spleen (A) and intraepithelial lymphocytes (IELs, B) at days 7 and/or 14 after allogeneic bone marrow transplantation (allo-BMT) (n = 6–8 per group, pooled from 2 experiments). (C–E) CD69+ (C) and α4β7+ (D) expression of donor T cells in the spleen at day 14 after allo-BMT (n = 7–8 per group, pooled from 2 experiments). *P < 0.05. (E) Donor IFN-γ–producing T cells in the spleen at day 14 after allo-BMT (n = 7–8 per group, pooled from 2 experiments). *P < 0.05. (F) Serum IFN-γ levels at day 14 after allo-BMT (n = 8–10 per group, pooled from 3 experiments). *P < 0.05. (G) T cell competition assay. BALB/c animals were lethally irradiated with 8.5 Gy on day –1 and received 1 × 106 T cells from both B6 WT (CD45.1+) and B6 Siglec-G–/– (CD45.2+) animals on day 0. On day 4 after transfer, spleens from BALB/c animals were isolated and analyzed. The percentages of CD45.1+ and CD45.2+ T cells in the spleen of BALB/c animals are shown. Combined data from 3 individual experiments are shown. Unpaired t test (A–G). *P < 0.05, ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts